Brought to you by 
Glaxo makes unsolicited offer to buy HGS for $2.6bn; now finalized
04 Feb 2021
Executive Summary
GlaxoSmithKline PLC has made a hostile bid to acquire public top-tier biotech Human Genome Sciences Inc., which immediately rejected the $13-per-share offer (a 73% premium) valuing HGS at $2.6bn. HGS says it will be exploring strategic alternatives, including a possible sale, and did request additional information from GSK.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo makes unsolicited offer to buy HGS for $2.6bn; now finalized
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice